Quantcast

SenoRx Announces Court Grants Jointly Requested Stay of Proceedings

June 24, 2008

ALISO VIEJO, Calif., June 24, 2008 (PRIME NEWSWIRE) — SenoRx (Nasdaq:SENO) today announced that the United States District Court for the Northern District of California has granted a joint request by Hologic and SenoRx to stay all proceedings in the case currently pending between the parties, including the Markman claims construction hearing (previously scheduled for June 25, 2008) and trial (previously scheduled to begin on July 14, 2008), for at least sixty days in order to provide the parties time to discuss possible resolution of the matter.

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx has recently launched several of its products through distributors in more than 15 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company’s website at www.senorx.com.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  SenoRx, Inc.           Lila Churney, Director of Investor Relations           949-362-4800 x132 



comments powered by Disqus